Nurix Therapeutics Presents Positive Clinical Data from Its Novel Bruton’s Tyrosine Kinase (BTK) Degrader Programs, NX-5948 and NX-2127, at the 65th American Society of Hematology (ASH) Annual Meeting Portfolio News / Karina Tin December 11, 2023 Nurix Therapeutics Presents Positive Clinical Data from Its Novel Bruton’s Tyrosine Kinase (BTK) Degrader Programs, NX-5948 and NX-2127, at the 65th American Society of Hematology (ASH) Annual Meeting Read More »
Initial Phase 1 Dose Escalation Data for ORIC-533 in Relapsed/Refractory Multiple Myeloma Demonstrates Clinical Activity and Strong Safety Profile Supporting Potential for Combination Development Portfolio News / Karina Tin December 11, 2023 Initial Phase 1 Dose Escalation Data for ORIC-533 in Relapsed/Refractory Multiple Myeloma Demonstrates Clinical Activity and Strong Safety Profile Supporting Potential for Combination Development Read More »
Plexium Initiates Dosing in Phase 1 Study of PLX-4545, a Potent and Selective Degrader of the Transcription Factor IKZF2 Portfolio News / Karina Tin December 11, 2023 Plexium Initiates Dosing in Phase 1 Study of PLX-4545, a Potent and Selective Degrader of the Transcription Factor IKZF2 Read More »
Carmot Therapeutics Enters into Definitive Merger Agreement with Roche Portfolio News / Karina Tin December 4, 2023 Carmot Therapeutics Enters into Definitive Merger Agreement with Roche Read More »
Neurona Therapeutics Presents New Clinical Data from First Cohort in Ongoing Phase I/II Open-Label Trial of NRTX-1001 Cell Therapy for Drug-resistant Mesial Temporal Lobe Epilepsy (MTLE) Portfolio News / Karina Tin December 1, 2023 Neurona Therapeutics Presents New Clinical Data from First Cohort in Ongoing Phase I/II Open-Label Trial of NRTX-1001 Cell Therapy for Drug-resistant Mesial Temporal Lobe Epilepsy (MTLE) Read More »
Escient Pharmaceuticals Initiates Clinical Proof-of-Concept Study of EP262, A First-in-Class Oral MRGPRX2 Antagonist, In Atopic Dermatitis Portfolio News / Karina Tin November 28, 2023 Escient Pharmaceuticals Initiates Clinical Proof-of-Concept Study of EP262, A First-in-Class Oral MRGPRX2 Antagonist, In Atopic Dermatitis Read More »
RAPT Therapeutics Announces Publication of Phase 1A/1B Clinical Trial of Zelnecirnon (RPT193) To Treat Atopic Dermatitis In Allergy Portfolio News / Karina Tin November 27, 2023 RAPT Therapeutics Announces Publication of Phase 1A/1B Clinical Trial of Zelnecirnon (RPT193) To Treat Atopic Dermatitis In Allergy Read More »
Carmot Therapeutics Commenced Phase 2 Clinical Trial of Novel Dual GLP-1/GIP Receptor Agonist CT-868 for the Treatment of Type 1 Diabetes Portfolio News / Karina Tin November 15, 2023 Carmot Therapeutics Commenced Phase 2 Clinical Trial of Novel Dual GLP-1/GIP Receptor Agonist CT-868 for the Treatment of Type 1 Diabetes Read More »
RAPT Therapeutics Reports Third Quarter 2023 Financial Results Portfolio News / Karina Tin November 13, 2023 RAPT Therapeutics Reports Third Quarter 2023 Financial Results Read More »
NGM Bio Presents Positive Phase 2b Results from the ALPINE 4 Trial of Aldafermin in Patients with Compensated Cirrhosis (F4) Due to NASH at AASLD The Liver Meeting® Portfolio News / Karina Tin November 13, 2023 NGM Bio Presents Positive Phase 2b Results from the ALPINE 4 Trial of Aldafermin in Patients with Compensated Cirrhosis (F4) Due to NASH at AASLD The Liver Meeting® Read More »